Pozen (POZN) presents positive results from two pivotal Phase 3 clinical trials of the...
Tuesday, November 6, 2012, 6:11 PM ETPozen (POZN) presents positive results from two pivotal Phase 3 clinical trials of the investigational product, PA32540, a treatment for gastric ulcers, at The American Heart Association Scientific Sessions 2012. The drug, which consists of a tablet with enteric-coated aspirin coupled with immediate-release Omeprazole, showed that patients on PA32540 experienced fewer gastric ulcers compared to those taking enteric-coated aspirin alone.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles